Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.
Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.
Kokolis
Spyros
S
State University of New York, Health Science Center at Brooklyn, 11203, USA.
Cavusoglu
Erdal
E
Clark
Luther T
LT
Marmur
Jonathan D
JD
D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006490:Hemostatics / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D013577:Syndrome; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006490:Hemostatics; D006495:Heparin, Low-Molecular-Weight; D013917:Thrombin